In this article, we will look at the 10 Best Healthcare Stocks to Buy for the Long Term.
On May 7, Haig Bathgate, CEO of Callanish Capital, appeared on CNCB to talk about his bullish view on the global markets amid the Iran war, and how its impact would be short-lived, especially when compared to the bigger and long-term worries for the market, such as concerns over capex spend and the AI boom.
He was of the view that we should always look back into history, as it is very easy to get swayed by and caught up in the emotions of what is happening in the short term. The reality, he stated, is that wars have a very limited long-term impact on stock markets. While we will see some effects, with some sectors affected more than others, the long-term impact is usually relatively short-lived, which is why he is trying to look through that.
READ ALSO: 10 Best Performing Healthcare Stocks So Far in 2026 AND 10 Best Strong Buy Stocks to Invest in According to Billionaires.
Bathgate further stated that before we entered into this war, the US stock markets had been accelerating into the tail end of last year. Therefore, he is trying to assess the long-term nature of what happens with AI, energy supply, and long-term drivers of underlying profitability in the markets, which is driven by things that are very different from what we are seeing in the Middle East at the moment.
With these broader market trends in view, let’s narrow down and look at the best healthcare stocks to buy for the long term.
Our Methodology
We used the Finviz stock screener to identify the best high-growth healthcare stocks with a forward P/E below 15 and selected the top 10 stocks most popular among hedge funds as of Q4 2025, using the hedge fund sentiment data from Insider Monkey’s database. The stocks are arranged in ascending order of hedge fund sentiment.
Note: All data was recorded on May 8.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Healthcare Stocks to Buy for the Long Term
10. AdaptHealth Corp. (NASDAQ:AHCO)
Number of Hedge Fund Holders: 22
AdaptHealth Corp. (NASDAQ:AHCO) is one of the best healthcare stocks to buy for the long term. Canaccord lifted the price target on AdaptHealth Corp. (NASDAQ:AHCO) to $16 from $14 on May 7, reiterating a Buy rating on the shares. The firm updated its model after the company released its fiscal Q1 results, where EBITDA missed estimates and caused a pullback in the shares. It added that AdaptHealth Corp. (NASDAQ:AHCO) appears to be uniquely positioned in the DME market to gain share, especially if the demand environment for capitated agreements becomes the preferred method to better serve patients with chronic conditions.
AdaptHealth Corp. (NASDAQ:AHCO) released its fiscal Q1 2026 results on May 5, with net revenue for the quarter coming up to $819.8 million compared to $777.9 million, reflecting an increase of 5.4%. The company also reported organic revenue growth of 9.1%, with growth across each of the reportable segments. Net loss attributable to the company was $16.0 million.
AdaptHealth Corp. (NASDAQ:AHCO) provides home healthcare equipment, supplies, and related services. The company’s focus is on sleep therapy equipment for obstructive sleep apnea, oxygen, and related chronic therapy services, HME medical devices and supplies for wound care, diabetes, urological, and more.
9. Phibro Animal Health Corporation (NASDAQ:PAHC)
Number of Hedge Fund Holders: 25
Phibro Animal Health Corporation (NASDAQ:PAHC) is one of the best healthcare stocks to buy for the long term. Phibro Animal Health Corporation (NASDAQ:PAHC) announced on May 6 financial results for its third quarter ended March 31, 2026, along with updated financial guidance for the year ending June 30, 2026. The company reported net sales of $383.5 million for the quarter, reflecting an increase of $35.7 million, or 10%, from the prior year period. Net income reached $24.0 million, an increase of $3.1 million, or 15%, with diluted earnings per share of $0.59, an increase of $0.08, or 16% from the prior year period.
Phibro Animal Health Corporation (NASDAQ:PAHC) attributed the positive results to continued strength in the company’s Animal Health business, where sales rose 13%, backed by strong demand across MFAs, vaccines, and nutritional specialties. The company also updated its fiscal year 2026 guidance, which includes net sales of $1.46 billion to $1.50 billion and adjusted EBITDA of $247 million to $255 million.
Phibro Animal Health Corporation (NASDAQ:PAHC) develops, manufactures, and markets animal health and mineral nutrition products. Its operations are divided into the following segments: Animal Health, Mineral Nutrition, and Performance Products.
